Lexeo Therapeutics, Inc. financial data

Symbol
LXEO on Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
Location
345 Park Avenue South, Floor 6, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2024 - Aug 12, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 667 %
Debt-to-equity 38.9 %
Return On Equity -103 % -297%
Return On Assets -51.5 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 33.1M shares
Common Stock, Shares, Outstanding 33M shares
Entity Public Float 0 USD
Common Stock, Value, Issued 3K USD
Weighted Average Number of Shares Outstanding, Basic 33M shares +1938%
Weighted Average Number of Shares Outstanding, Diluted 33M shares +1938%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 57.8M USD +47.4%
General and Administrative Expense 24.3M USD +155%
Operating Income (Loss) -82.1M USD -68.5%
Nonoperating Income (Expense) 4.87M USD +333%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -77.2M USD -58%
Net Income (Loss) Attributable to Parent -77.2M USD -21.2%
Earnings Per Share, Basic 6.07 USD/shares +92.3%
Earnings Per Share, Diluted 6.07 USD/shares +92.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 175M USD
Other Assets, Current 3K USD -99.2%
Assets, Current 177M USD
Property, Plant and Equipment, Net 1.21M USD
Operating Lease, Right-of-Use Asset 8.78M USD
Assets 192M USD
Accounts Payable, Current 5.77M USD
Liabilities, Current 18.9M USD
Operating Lease, Liability, Noncurrent 7.14M USD
Liabilities 27.1M USD
Retained Earnings (Accumulated Deficit) -225M USD
Stockholders' Equity Attributable to Parent 165M USD
Liabilities and Equity 192M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -14.9M USD +19.1%
Net Cash Provided by (Used in) Financing Activities 88.7M USD
Net Cash Provided by (Used in) Investing Activities -193K USD
Common Stock, Shares Authorized 500M shares
Common Stock, Shares, Issued 33.1M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 73.6M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 178M USD +265%
Deferred Tax Assets, Valuation Allowance 62M USD +63.1%
Deferred Tax Assets, Gross 65.3M USD +54.7%
Operating Lease, Liability 9.24M USD
Payments to Acquire Property, Plant, and Equipment 185K USD
Lessee, Operating Lease, Liability, to be Paid 11.4M USD
Property, Plant and Equipment, Gross 1.73M USD
Operating Lease, Liability, Current 2.1M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.21M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 2.15M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 2.15M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.26M USD
Deferred Tax Assets, Operating Loss Carryforwards 21.9M USD +42.4%
Preferred Stock, Shares Authorized 10M shares
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.32M USD
Operating Lease, Payments 2.29M USD +2.56%
Deferred Tax Assets, Net of Valuation Allowance 3.37M USD -20.5%
Share-based Payment Arrangement, Expense 6.85M USD +194%
Interest Expense 174K USD -34%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares